MeSH D050197 - atherosclerosis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Sanofi | Alirocumab | Praluent |  | 2015-09-23 |  |  |
| Daiichi Pharmaceutical | Bempedoic acid | Nilemdo |  | 2020-04-01 |  |  |
| Bempedoic acid, Ezetimibe | Nustendi |  | 2020-03-27 |  |  | |
| Amgen | Evolocumab | Repatha |  | 2015-08-27 | $2,222 M | Y2024 |
| Esperion Therapeutics | Bempedoic acid | Nexletol | 2023-12-23 | 2020-02-21 |  |  |
| Bempedoic acid, Ezetimibe | Nexlizet | 2023-12-23 | 2020-02-26 |  |  | |
| Regeneron Pharmaceuticals | Alirocumab | Praluent |  | 2015-07-24 | $240.3 M | Q4/23-Q3/24 |
Clinical Trials
Historical Success Rate
Phase 1
70%21/30
Phase 2
59%36/61
Phase 3
42%27/64
Approved: 3Overall Success rate: 17%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use